InSilico Medicine

Develops an AI platform for drug development to treat cancer and age-related diseases.

Launch date

2014

Employees

Market cap

Enterprise valuation

€1.0b (Public information from Aug 2022)

Yuen Long District New Territories (HQ)

Revenues, earnings & profits over time

USD	2021	2022
Revenues	40.2m	48.8m
% growth	-	21 %

Date	Investors	Amount	Round
-	SoGal Ventures HongShan LongeVC	N/A	-
Apr 2014	Deep Knowledge Ventures	$300k	Seed
Nov 2014	Deep Knowledge Ventures	$1.2m	Convertible
Feb 2017	Jim Mellon A-Level Capital	$10.0m	Early VC
Jul 2017	N/A	$4.0m	Series A
Jun 2018	WuXi AppTec Pavilion Capital Partners Bold Capital Partners Juvenescence	$6.0m	Series A
Sep 2019*	Eight Roads Ventures Pavilion Capital Partners F-Prime Sinovation Ventures Bold Capital Partners Lilly Asia Ventures Qiming Venture Partners Juvenescence Baidu Ventures	$37.0m	Series B
Apr 2020*	N/A	N/A	Series B
Jun 2021*	Warburg Pincus	$255m	Series C
Jun 2022*	Warburg Pincus Pavilion Capital Partners B Capital Group Bold Capital Partners Qiming Venture Partners Alex Zhavoronkov BHR Partners	$60.0m Valuation: $1.1b	Series D
Aug 2022*	Prosperity7vc	$35.0m Valuation: $1.1b	Series D
Total Funding		€371m

ACQUISITION by Regent Pacific Sep 2020

Financials